Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19399365 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL22769540 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL15429687 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL36997213 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL18464579 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL24768202 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL36392634 | 1.00 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL22259843 | 0.86 | NPC1 (0.38) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL20833308 | 0.86 | NPC1 (0.38) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL22260399 | 0.77 | SCN10A (0.39) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-20210130821-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-06 | — | — | US | disclosed |
| US-10590413-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2020-03-17 | — | — | US | disclosed |
| US-9982257-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9885037-B2 | — | — | 2018-02-06 | — | — | US | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130821-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
| US-20170275621-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
| US-10590413-B2 | Chiral control | RNGTT, POLI, NSUN3 | SLC6A3 3354/4885SLC6A2 3205/4885SLC6A4 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.